New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
08:58 EDTJNJ, MRK, ABBV, IDIXIdenix buyout price result of bidding war, CNBC's Faber reports
The premium Merck (MRK) paid for Idenix (IDIX) was the result of an "all out bidding war" between Merck, Johnson & Johnson (JNJ) and AbbVie (ABBV), CNBC's David Faber reports via Twitter.
News For IDIX;MRK;JNJ;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 18, 2015
12:31 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
February 17, 2015
18:06 EDTABBVPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:29 EDTJNJ Boston Scientific announces settltement of merger agreement lawsuit
Subscribe for More Information
07:04 EDTJNJGTx names Robert Wills as executive chairman
Subscribe for More Information
February 13, 2015
09:07 EDTABBVDeutsche Bank biotech analyst holds an analyst/industry conference call
Biotech Analyst Karnauksas discusses AbbVie's product pipeline in an Analyst/Industry conference call to be held on February 13 at 10 am.
08:23 EDTJNJPiper Jaffray biotech/healthcare analysts hold analyst/industry conference call
Subscribe for More Information
08:19 EDTMRKAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information
06:13 EDTABBVShire says $1.6B break fee from AbbVie is not taxable, Financial Times reports
Subscribe for More Information
05:09 EDTJNJStocks with implied volatility movement; JNJ NUGT
Subscribe for More Information
February 12, 2015
16:02 EDTJNJOptions Update; February 12, 2015
Subscribe for More Information
15:12 EDTJNJJ&J Remicade appeal process could take years to resolve, says Wells Fargo
Subscribe for More Information
15:00 EDTJNJEPIRUS gains after J&J patent for Remicade rejected by USPTO
Shares of small-cap pharmaceutical company EPIRUS Biopharmaceuticals (EPRS) are rising in afternoon trading after Johnson & Johnson (JNJ) confirmed earlier that the U.S. Patent and Trademark Office issued a final rejection of patent '471 patent relating to infliximab, which is sold with the trade name Remicade. EPIRUS is focused on the research, development, manufacturing and commercialization of biosimilar therapeutics and its pipeline includes BOW015, a biosimilar version of infliximab. In afternoon trading, shares of EPIRUS rose 83c, or 14%, to $6.72.
14:36 EDTJNJJ&J confirms USPTO issues final rejection of Remicade '471 patent
Subscribe for More Information
12:30 EDTJNJJohnson & Johnson Remicade patent rejected by USPTO, says Goldman
Goldman Sachs notes the United States Patent and Trademark Office completed the re-examination of Johnson & Johnson's Remicade patent and issued a rejection. Goldman now sees increased risk of a biosimilar version of Remicade launching earlier than expected, possibly in 2015. It keeps a Sell rating on the stock with a $96 price target. Shares of J&J are down 2% to $98.70 in midday trading.
12:19 EDTJNJJ&J Remicade patent rejected in re-exam by USPTO, Bloomberg reports
Subscribe for More Information
06:34 EDTABBVEnanta partner AbbVie submits hepatitis C NDA to Japanese regulating agency
Subscribe for More Information
05:28 EDTABBVAbbVie submits new drug application in Japan for hepatitis C treatment
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use